316 related articles for article (PubMed ID: 8443918)
1. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Collen D; De Cock F; Stassen JM
Circulation; 1993 Mar; 87(3):996-1006. PubMed ID: 8443918
[TBL] [Abstract][Full Text] [Related]
2. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
3. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
Lijnen HR; Stassen JM; Vanlinthout I; Fukao H; Okada K; Matsuo O; Collen D
Thromb Haemost; 1991 Oct; 66(4):468-73. PubMed ID: 1796398
[TBL] [Abstract][Full Text] [Related]
4. On the immunogenicity of recombinant staphylokinase in patients and in animal models.
Vanderschueren SM; Stassen JM; Collen D
Thromb Haemost; 1994 Aug; 72(2):297-301. PubMed ID: 7831668
[TBL] [Abstract][Full Text] [Related]
5. Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model.
Vanderschueren S; Stassen JM; Collen D
J Cardiovasc Pharmacol; 1996 Jun; 27(6):809-15. PubMed ID: 8761847
[TBL] [Abstract][Full Text] [Related]
6. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
7. Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Collen D; Lijnen HR; Vanderschueren S
Verh K Acad Geneeskd Belg; 1995; 57(3):183-96; discussion 196-8. PubMed ID: 7483814
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1995 May; 73(5):845-9. PubMed ID: 7482414
[TBL] [Abstract][Full Text] [Related]
9. Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction.
Collen D; Moreau H; Stockx L; Vanderschueren S
Circulation; 1996 Jul; 94(2):207-16. PubMed ID: 8674180
[TBL] [Abstract][Full Text] [Related]
10. [Thrombolytic effects of recombinant staphylokinase on coronary thrombosis in miniature pigs].
Li G; Fang XL; Ren Z; Li KQ; Zhou SH; Hu DQ; Wu GQ; Wang TL; Li WP
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2020 Jul; 36(4):369-374. PubMed ID: 33167101
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and thrombolytic potential of staphylokinase.
Lijnen HR
Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
Nagai N; Vanlinthout I; Collen D
Circulation; 1999 Dec 21-28; 100(25):2541-6. PubMed ID: 10604893
[TBL] [Abstract][Full Text] [Related]
13. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots.
Lian Q; Szarka SJ; Ng KK; Wong SL
J Biol Chem; 2003 Jul; 278(29):26677-86. PubMed ID: 12736246
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
Hauptmann J; Glusa E
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
[TBL] [Abstract][Full Text] [Related]
15. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs KH; Lijnen HR
Eur J Biochem; 1993 Aug; 216(1):307-14. PubMed ID: 7689966
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in the hamster.
Stassen JM; Nyström A; Hoylaerts M; Collen D
Circulation; 1995 Mar; 91(5):1330-5. PubMed ID: 7867170
[TBL] [Abstract][Full Text] [Related]
18. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
Aisina RB; Moukhametova LI; Varfolomeyev SD
Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
[TBL] [Abstract][Full Text] [Related]
19. Fibrin-specific fibrinolysis induced by recombinant staphylokinase.
Shishido Y; Matsumoto T; Sakai M; Kaneda N; Sansawa H; Shimura K; Hashimoto S; Yokokura T
Biol Pharm Bull; 1994 Aug; 17(8):1060-4. PubMed ID: 7820108
[TBL] [Abstract][Full Text] [Related]
20. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
Nedaeinia R; Faraji H; Javanmard SH; Ferns GA; Ghayour-Mobarhan M; Goli M; Mashkani B; Nedaeinia M; Haghighi MHH; Ranjbar M
Mol Biol Rep; 2020 Jan; 47(1):819-841. PubMed ID: 31677034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
